Clinical Trials Sponsored by Epic Sciences

Total 19458 results

Gilead Sciences

Completed

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

LQT2 Syndrome

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic
Gilead Sciences

Terminated

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

Japan
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Chronic Hepatitis C Virus

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

HIV-1 Infection

Spain, United Kingdom, France, Italy, Belgium
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Hepatitis C Virus

United States, New Zealand
Gilead Sciences

Approved for marketing

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

SARS-CoV2 Infection

United States, Israel, Belgium, Spain, Australia, Denmark, Italy, Germany, France, Portugal, United Kingdom, Poland, Switzerland, Canada, Austria, Cyprus, Czechia, Estonia, Greece, Hungary, Iceland, Ireland, Lithuania, Netherlands, Romania and more
Gilead Sciences

Completed

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Chronic Hepatitis B

Canada, United States, Korea, Republic of, Italy, Netherlands, New Zealand
Gilead Sciences

Completed

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Nonalcoholic Steatohepatitis (NASH)

United States
Gilead Sciences

Completed

Study of Ambrisentan in Participants With Pulmonary Hypertension (ABS-LT)

Pulmonary Hypertension

United States, Australia, Argentina, Canada, Mexico, Brazil, Chile, Russian Federation, Ukraine
Gilead Sciences

Completed

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Spain, United States, Hungary, United Kingdom, Italy, France, Poland, Australia, Belgium
Gilead Sciences

Completed

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis (NASH)

United States
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Chronic Hepatitis B

Italy, United Kingdom, United States, Taiwan, Korea, Republic of, Canada, New Zealand, Hong Kong
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4)

Nonalcoholic Steatohepatitis

United States, Spain, Hong Kong, Canada, Belgium, Australia, Taiwan, India, Japan, Korea, Republic of, Singapore, United Kingdom, Israel, Puerto Rico, France, New Zealand, Germany, Austria, Italy, Mexico, Poland, Switzerland
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
Gilead Sciences

Completed

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States, Puerto Rico, New Zealand
Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
Gilead Sciences

Completed

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States, Puerto Rico, New Zealand
Gilead Sciences

Completed

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Hepatitis C Virus Infection

United States, France
Gilead Sciences

Completed

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

HIV Infections | HIV

United States, Netherlands, Spain, Mexico, France, Thailand, Australia, United Kingdom, Dominican Republic
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (ESRD)

Hepatitis C Virus Infection

United States, Taiwan, Belgium, Germany, Italy
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Hepatitis C Virus Infection

United States, New Zealand, Australia, United Kingdom
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
Gilead Sciences

Terminated

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States, Canada, Germany
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
Gilead Sciences

Completed

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Long QT Syndrome

United States, Romania, New Zealand, Germany
Gilead Sciences

Completed

Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

Chronic Hepatitis B

Korea, Republic of, Canada, United States, New Zealand, Italy, Romania
Gilead Sciences

Terminated

Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection

Hepatitis B

Spain, Italy, United Kingdom, Romania, Belgium, France, Greece
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, France, United Kingdom, Germany, Italy
Gilead Sciences

Terminated

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Colorectal Cancer

Spain, United States, Germany, Italy, Russian Federation, Poland, France
Gilead Sciences

Completed

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (RETRO-idel)

Chronic Lymphocytic Leukaemia

United Kingdom, Ireland
Gilead Sciences

Terminated

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Australia, France, Poland, Ukraine, Switzerland, Romania, Canada, Netherlands, Korea, Republic of, Belgium, Russian Federation, Taiwan, New Zealand, Hungary, United Kingdom, Bulgaria, Latvia, Czechia, Slovakia, Italy and more
Gilead Sciences

Completed

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (TEMPO)

Ventricular Arrhythmia

Netherlands, Israel, United States, Denmark, Canada, Germany, Czechia, Hungary, Poland
Gilead Sciences

Terminated

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH (NASH)

Liver Fibrosis Due to NASH

United States, Canada, France, Italy, Germany, Puerto Rico, Spain, United Kingdom
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Hepatitis C Virus Infection

Japan
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Hepatitis C Virus Infection

United States
Gilead Sciences

Terminated

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

Spain, Korea, Republic of, United States, Germany, Canada, France, United Kingdom
Gilead Sciences

Withdrawn

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Diffuse Large B-Cell Lymphoma | Mediastinal B-cell Lymphoma

Italy, Spain, France, Poland
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Hepatitis C Virus Infection

France, Austria, Germany, Italy
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, Canada, Spain, Australia, Italy, United Kingdom, Belgium, Croatia, France, Hungary, Poland, Romania, Czechia
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

United States
Gilead Sciences

Completed

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Hepatitis C Virus Infection

United States, New Zealand, Puerto Rico, Australia
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Gilead Sciences

Terminated

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

Hepatitis C Virus Infection

Japan

3

Subscribe